Bristol-Myers Squibb Company
TGF Beta RECEPTOR ANTAGONISTS
Last updated:
Abstract:
The invention relates generally to compounds that modulate the activity of TGF.beta.R-1 and TGF.beta.R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Status:
Application
Type:
Utility
Filling date:
19 Jul 2017
Issue date:
26 Sep 2019